Antitumor Chrysene derivatives

Details Antitumor Chrysene derivatives Antitumor Chrysene derivatives

1998-10-27

2000-01-18

McKane, Joseph K.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

5142375, 5142378, 514252, 514255, 514319, 514354, 514357, 514408, 514423, 544 59, 544154, 544360, 546195, 546285, 548528, A61K 3139, C07D29503

Patent

active

060158115

ABSTRACT:
Chrysene derivatives having the formula ##STR1## have been found to have antitumor activity. In the above formula, at least one of R.sub.1 -R.sub.12 is --R.sub.13 Z, where R.sub.13 is a substituted or unsubstituted amino or amido group having from 1-12 carbon atoms, and Z is a substituted or unsubstituted heterocyclic group having from 1-12 carbon atoms; and the remainder of R.sub.1 -R.sub.12 are independently selected from the group consisting of hydrogen, substituted or unsubstituted amino or amido groups having 1-12 carbon atoms, nitro, and substituted or unsubstituted hydrocarbyl groups having from 1-12 carbon atoms.

REFERENCES:
Cheubim et al., "Synthesis and biological evaluation of phenathrene-derived carboxamides as cytotoxic agents," Anti-Cancer Drug Design, vol. 8, pp. 429-438 (1993).
Sami et al., "2-Substituted 1,2-Dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones. A New Class of Antitumor Agent," J. Med. Chem., vol. 36, No. 6, pp. 765-770 (1993).
Yu et al., "Phenothiazines as Lipid Peroxidation Inhibitors and Cytoprotective Agents," J. Med. Chem., vol. 35, No. 4, pp. 716-724 (1992).
Leon et al., "Modulation of the Antitumor Activity by Methyl Substitutions in the Series of 7H-Pyridocarbazole Monomers and Dimers," J. Med. Chem., vol. 30, No. 11, pp. 2074-2080 (1997).
Bair et al., "2-[Arylmethyl)amino]-2-methyl-1,3-propanediol DNA Intercalators. An Examination of the Effects of Aromatic Ring Variation on Antitumor Ring Variation on Antitumor Activity and DNA Binding," J. Med. Chem., vol. 34, No. 7, pp. 1983-1990 (1991).
Nakanishi et al., "Studies of Piperidine Derivatives," J. Med. Chem., vol. 13, No. 4, pp. 644-648 (1970).
"Chrysene," Polycyclic Aromatic Hydrocarbon Structure Index, No. 39, NIST Special Publication 922 (Aug. 18, 1998).
"7H-Benzo[hi]chrysene," Polycyclic Aromatic Hydrocarbon Structure Index, No. 106, NIST Special Publication 922 (Aug. 18, 1998).
"Dibenzo[c,1]chrysene," Polycyclic Aromatic Hydrocarbon Structure Index, No. 293, NIST Special Publication 922 (Aug. 18, 1998).
"Dibenzo[c,p]chrysene," Polycyclic Aromatic Hydrocarbon Structure Index, No. 276, NIST Special Publication 922 (Aug. 18, 1998).
"Dibenzo[def,mno]chrysene," Polycyclic Aromatic Hydrocarbon Structure Index, No. 121, NIST Special Publication 922 (Aug. 18, 1998).
Derwent Abstract, "Correlations between topological resonance energy of methyl-substituted benz[c]acridines, benzo[a]phenothiazines and crysenes, and their carcinogenic or antitumor activities," Kurihara et al., Anticancer. Res., 16(5A), pp. 2757-2765 (Sep.-Oct. 1996).
Derwent Abstract, "Use of precision-cut liver slices to evaluate species differences in 2-acetylaminofluorene-induced unscheduled DNA synthesis," Lake et al., Toxicol. Appl. Pharmacol., 138 (2), pp. 231-241 (Jun. 1996).
Derwent Abstract, "Absence of mutagenicity of benzo[c] phenathridine alkaloids in somatic cells of Drosophila melanogaster: comparison with 7,12-dimethylbena[a] anthr acene and crysene," Perez-Chiesa et al., Mutat. Res., 198 (4), pp. 277-283 (Feb. 1993).
Derwent Abstract, "Characterization of cytochrome P-450 2B6 in human liver microsomes," Mimura et al., Drug Metab. Dispos., 21 (6) pp. 1048-1056 (Nov.-Dec. 1993).
Derwent Abstract, "A phase II study of crisnatol mesylate in patients with ovarian carcinoma," Smalley et al., Invest. New Drugs, 10(2), pp. 107-112 (Jul. 1992).
Derwent Abstract, "An efficient multiple-exposure analysis of the toxicity of crisnatol, a DNA intercalator in phase II clinical trials," Zucker et al., Invest. New Drugs, 10 (1) pp. 1-15 (Apr. 1992).
Derwent Abstract, "New anticancer agents," Brown et al., Cancer, Chemother. Biol. Response Modif., 12, pp. 111-146 (1991).
Derwent Abstract, "Disposition, metabolism, and excretion of the anticancer agent crisnatol in the rat," Patel et al., Drug Metab. Dispos., 19 (2), pp. 491-497 (Mar.-Apr. 1991).
Derwent Abstract, "Metabolism of a novel antitumor agent, crisnatol, by a human hepatoma cell line", Patel et al., Biochem. Pharmacol., 42 (2), pp. 337-346 (Jul. 5, 1991).
Derwent Abstract, "Phase I evaluation of crisnatol (BWA77OU mesylate) on a monthly extended infusion schedule," Sel. Cancer Ther., 7 (2), pp. 85-91 (Summer 1991).
Derwent Abstract, "2-[(arylmethyl)amino]-2-methyl-1,3-propanediol DNA intercalators. An examination of the effects of aromatic ring variation on antitumor activity and DNA binding," J. Med. Chem., 34 (7), pp. 1983-1990 (Jul. 1991).
Derwent Abstract, "Crisnatol mesylate: phase I dose escalation by extending infusion duration," Poplin et al., Invest. New Drugs, 9 (1), pp. 41-47 (Feb. 1991).
Derwent Abstract, "In vitro pharmacodynamic assay for cancer drug development: application to crisnatol, a new DNA intercalator," Adams, Cancer Res., 49 (23) pp. 6615-6620 (Dec. 1, 1989).
Derwent Abstract, "Phase I and clinical pharmacology trial of crisnatol (BWA77OU mesylate) using a monthly single-dose schedule," Harman et al., Cancer Res., 48 (16) pp. 4706-4710 (Aug. 15, 1988).
Derwent Abstract, WO 9422773 (Oct. 13, 1994).
Derwent Abstract, RO 91292 (Feb. 28, 1983).
Derwent Abstract, RO 79546 (Jul. 30, 1982).
Derwent Abstract, RO 75308 (Feb. 17, 1982).
Derwent Abstract, JP 57020741 (Feb. 3, 1982).
Banik et al, "A Facile Reduction of Aromatic Nitro Compounds to Aromatic Amines by Samarium and Iodine," Tetrahedron Letters, vol. 39, pp. 7243-7246 (1998).
Banik et al, "Benzylic Oxidation by Sodium Bismuthate in Acetic Acid: A Simple Method for the Synthesis of Polycyclic Aromatic Ketones," Tetrahedron Letters, vol. 39, pp. 7247-7250 (1998).
"7H-Dibenzo[c,g]fluorene," Polycyclic Aromatic Hydrocarbon Structure Index, No. 85, NIST Special Publication 922 (Aug. 17, 1998).
"13H-Dibenzo[a,i]fluorene," Polycyclic Aromatic Hydrocarbon Structure Index, No. 92, NIST Special Publication 922 (Aug. 17, 1998).
"12H-Dibenzo[b,h]fluorene," Polycyclic Aromatic Hydrocarbon Structure Index, No. 96, NIST Special Publication 922 (Aug. 17, 1998).
"7H-Dibenzo[b,g]fluorene," Polycyclic Aromatic Hydrocarbon Structure Index, No. 88, NIST Special Publication 922 (Aug. 17, 1998).
"13H-Dibenzo[a,h]fluorene," Polycyclic Aromatic Hydrocarbon Structure Index, No. 97, NIST Special Publication 922 (Aug. 17, 1998).
"13H-Dibenzo[a,g]fluorene," Polycyclic Aromatic Hydrocarbon Structure Index, No. 90, NIST Special Publication 922 (Aug. 17, 1998).
Alunni-Bistocchi et al., J. Heterocyclic Chem. 17:993-995 (1980).
Groupe Europeen du Cancer Sein, Europ. J. Cancer 3:75-77 (1967).

Affiliated with

Also associated with

Rating

Antitumor Chrysene derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antitumor Chrysene derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antitumor Chrysene derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-563675